204 related articles for article (PubMed ID: 17513795)
1. Novel insight into the agonistic mechanism of alefacept in vivo: differentially expressed genes may serve as biomarkers of response in psoriasis patients.
Haider AS; Lowes MA; Gardner H; Bandaru R; Darabi K; Chamian F; Kikuchi T; Gilleaudeau P; Whalen MS; Cardinale I; Novitskaya I; Krueger JG
J Immunol; 2007 Jun; 178(11):7442-9. PubMed ID: 17513795
[TBL] [Abstract][Full Text] [Related]
2. Selective targeting of T cell subsets: focus on alefacept - a remittive therapy for psoriasis.
Krueger GG
Expert Opin Biol Ther; 2002 Apr; 2(4):431-41. PubMed ID: 11955280
[TBL] [Abstract][Full Text] [Related]
3. Alefacept (anti-CD2) causes a selective reduction in circulating effector memory T cells (Tem) and relative preservation of central memory T cells (Tcm) in psoriasis.
Chamian F; Lin SL; Lee E; Kikuchi T; Gilleaudeau P; Sullivan-Whalen M; Cardinale I; Khatcherian A; Novitskaya I; Wittkowski KM; Krueger JG; Lowes MA
J Transl Med; 2007 Jun; 5():27. PubMed ID: 17555598
[TBL] [Abstract][Full Text] [Related]
4. Enforced expression of GATA-3 during T cell development inhibits maturation of CD8 single-positive cells and induces thymic lymphoma in transgenic mice.
Nawijn MC; Ferreira R; Dingjan GM; Kahre O; Drabek D; Karis A; Grosveld F; Hendriks RW
J Immunol; 2001 Jul; 167(2):715-23. PubMed ID: 11441075
[TBL] [Abstract][Full Text] [Related]
5. Alefacept, an immunomodulatory recombinant LFA-3/IgG1 fusion protein, induces CD16 signaling and CD2/CD16-dependent apoptosis of CD2(+) cells.
da Silva AJ; Brickelmaier M; Majeau GR; Li Z; Su L; Hsu YM; Hochman PS
J Immunol; 2002 May; 168(9):4462-71. PubMed ID: 11970990
[TBL] [Abstract][Full Text] [Related]
6. Alefacept reduces infiltrating T cells, activated dendritic cells, and inflammatory genes in psoriasis vulgaris.
Chamian F; Lowes MA; Lin SL; Lee E; Kikuchi T; Gilleaudeau P; Sullivan-Whalen M; Cardinale I; Khatcherian A; Novitskaya I; Wittkowski KM; Krueger JG
Proc Natl Acad Sci U S A; 2005 Feb; 102(6):2075-80. PubMed ID: 15671179
[TBL] [Abstract][Full Text] [Related]
7. Clinical response to alefacept: results of a phase 3 study of intramuscular administration of alefacept in patients with chronic plaque psoriasis.
Ortonne JP
J Eur Acad Dermatol Venereol; 2003 Jul; 17 Suppl 2():12-6. PubMed ID: 12795770
[TBL] [Abstract][Full Text] [Related]
8. Use of Alefacept for Preconditioning in Multiply Transfused Pediatric Patients with Nonmalignant Diseases.
Stenger EO; Chiang KY; Haight A; Qayed M; Kean L; Horan J
Biol Blood Marrow Transplant; 2015 Oct; 21(10):1845-52. PubMed ID: 26095669
[TBL] [Abstract][Full Text] [Related]
9. Changes in circulating lymphocyte subpopulations following administration of the leucocyte function-associated antigen-3 (LFA-3)/IgG1 fusion protein alefacept.
Larsen R; Ryder LP; Svejgaard A; Gniadecki R
Clin Exp Immunol; 2007 Jul; 149(1):23-30. PubMed ID: 17403057
[TBL] [Abstract][Full Text] [Related]
10. Humanized anti-CD2 monoclonal antibody treatment of plaque psoriasis: efficacy and pharmacodynamic results of two randomized, double-blind, placebo-controlled studies of intravenous and subcutaneous siplizumab.
Bissonnette R; Langley RG; Papp K; Matheson R; Toth D; Hultquist M; Geba GP; White B
Arch Dermatol Res; 2009 Jul; 301(6):429-42. PubMed ID: 19471949
[TBL] [Abstract][Full Text] [Related]
11. Impaired CD4 and CD8 effector function and decreased memory T cell populations in ICOS-deficient patients.
Takahashi N; Matsumoto K; Saito H; Nanki T; Miyasaka N; Kobata T; Azuma M; Lee SK; Mizutani S; Morio T
J Immunol; 2009 May; 182(9):5515-27. PubMed ID: 19380800
[TBL] [Abstract][Full Text] [Related]
12. The effect of topical corticosteroids in combination with alefacept on circulating T-cell subsets in psoriasis.
Langewouters AM; Bovenschen HJ; De jong EM; Van Erp PE; Van De Kerkhof PC
J Dermatolog Treat; 2007; 18(5):279-85. PubMed ID: 17852631
[TBL] [Abstract][Full Text] [Related]
13. Selective targeting of human alloresponsive CD8+ effector memory T cells based on CD2 expression.
Lo DJ; Weaver TA; Stempora L; Mehta AK; Ford ML; Larsen CP; Kirk AD
Am J Transplant; 2011 Jan; 11(1):22-33. PubMed ID: 21070604
[TBL] [Abstract][Full Text] [Related]
14. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes.
Ellis CN; Krueger GG;
N Engl J Med; 2001 Jul; 345(4):248-55. PubMed ID: 11474662
[TBL] [Abstract][Full Text] [Related]
15. Prominent production of IL-20 by CD68+/CD11c+ myeloid-derived cells in psoriasis: Gene regulation and cellular effects.
Wang F; Lee E; Lowes MA; Haider AS; Fuentes-Duculan J; Abello MV; Chamian F; Cardinale I; Krueger JG
J Invest Dermatol; 2006 Jul; 126(7):1590-9. PubMed ID: 16645593
[TBL] [Abstract][Full Text] [Related]
16. Expression of IL-20 in synovium and lesional skin of patients with psoriatic arthritis: differential response to alefacept treatment.
Lebre MC; Jonckheere CL; Kraan MC; van Kuijk AW; Bos JD; de Rie M; Gerlag DM; Tak PP
Arthritis Res Ther; 2012 Sep; 14(5):R200. PubMed ID: 23006144
[TBL] [Abstract][Full Text] [Related]
17. Augmentation in expression of activation-induced genes differentiates memory from naive CD4+ T cells and is a molecular mechanism for enhanced cellular response of memory CD4+ T cells.
Liu K; Li Y; Prabhu V; Young L; Becker KG; Munson PJ; Weng Np
J Immunol; 2001 Jun; 166(12):7335-44. PubMed ID: 11390484
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic remodeling of the IL-2 and IFN-gamma loci in memory CD8 T cells is influenced by CD4 T cells.
Northrop JK; Thomas RM; Wells AD; Shen H
J Immunol; 2006 Jul; 177(2):1062-9. PubMed ID: 16818762
[TBL] [Abstract][Full Text] [Related]
19. A critical role for CD2 in both thymic selection events and mature T cell function.
Sasada T; Reinherz EL
J Immunol; 2001 Feb; 166(4):2394-403. PubMed ID: 11160298
[TBL] [Abstract][Full Text] [Related]
20. Expression of tolerance associated gene-1, a mitochondrial protein inhibiting T cell activation, can be used to predict response to immune modulating therapies.
Keeren K; Friedrich M; Gebuhr I; Philipp S; Sabat R; Sterry W; Brandt C; Meisel C; Grütz G; Volk HD; Sawitzki B
J Immunol; 2009 Sep; 183(6):4077-87. PubMed ID: 19684086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
